For patients with chronic conditions, the frustration is often not a lack of data, but its fragmentation. Patientory, a company founded in 2015, has spent nearly a decade building a blockchain-based answer to this problem. Its latest move, a pilot with a Korean insurer projected to generate up to $250,000 in annual recurring revenue, signals a hard pivot toward a pragmatic, regulated future [koreatechdesk.com, 2026].
From Token to Enterprise SaaS
Patientory's origin story is rooted in the early web3 health narrative. Founder Chrissa McFarlane launched the company with a focus on a consumer-facing blockchain health wallet and a native cryptocurrency, $PTOY [MM+M, 2018] [PTOY.org]. In recent years, the strategy has visibly shifted. According to a 2026 report, Patientory moved "from a token-centric web3 narrative to a compliance-first, enterprise SaaS model with recurring contracts and insurer pilots" [Hypepotamus, 2026].
The company now operates a dual-platform model:
- Neith Enterprise: A software platform for healthcare organizations, payers, and life sciences companies, providing population health analytics and AI-driven clinical trial recruitment [World Economic Forum, 2022] [MIT Solve, 2022].
- Patientory App: A consumer health data wallet that allows individuals to aggregate their records and participate in incentive programs, including a telemedicine weight management program called CareGLP [Patientory, 2026].
The Founder's Long Game
Driving this evolution is solo founder Chrissa McFarlane. Her profile is one of consistent advocacy within the digital health establishment, including serving as co-chair of a HIMSS Blockchain Workgroup [Halcyon] [HPN Online]. McFarlane has also steadily built a team with enterprise sales leadership and healthcare compliance expertise [Hypepotamus, 2026]. Patientory has raised an estimated $9.4 million across 13 rounds [Dealroom.co, 2026].
Traction and the Korean Beachhead
The most concrete signal of Patientory's new direction is its expansion into South Korea. The company reports consistent interest from Korean insurers and hospital innovation teams for AI-powered risk prediction and clinical trial matching [koreatechdesk.com, 2026]. This has materialized into a live enterprise pilot projected to onboard over 1,000 users in 2026, representing an estimated $150,000 to $250,000 in annual recurring revenue. This traction is backed by a notable investor roster that includes strategic corporate venture arms from pharmaceutical giants Novartis and GSK, as well as R/GA Ventures and Backstage Capital [Tracxn, 2024].
An Honest Counterfactual
The road ahead is not without significant hurdles:
- Technical and Commercial Complexity. Integrating with legacy hospital EHRs is notoriously difficult and slow [MM+M, 2018].
- Regulatory Scrutiny. Any platform handling protected health information is subject to HIPAA and similar regulations globally.
- Dual-Model Dilution. The company continues to maintain both a B2B enterprise platform and a B2C health app, which risks diluting resources.
Patientory's answer to these risks appears to be focus. The Korean pilot and the emphasis on Neith Enterprise suggest the B2B opportunity is the priority. The blockchain foundation is now framed less as a revolutionary token economy and more as a robust, auditable backend for secure health data exchange.
The Standard of Care Today
Patientory's bet is that a secure, patient-permissioned data layer can create a better baseline. By giving individuals a tool to aggregate their data and allowing enterprises to analyze that data with consent, the company aims to improve both personal health outcomes and systemic efficiency. The next twelve months will be critical in determining whether the Korean pilot can scale into a repeatable enterprise template.